Intelligence · Patents
Patents expiring in 2040
Annual patent cliff calendar for 2040 — US pharmaceutical patents by expiration date.
- Patents
- 1,866
Quick answer
1,866 indexed pharmaceutical patents have expiration dates in 2040. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 10874709
Conjugate of salicylic acid and peptide
granted -
US 10874748
Intervention for tendinopathy
granted -
US 10875907
Filovirus antibody
granted -
US 10875911
High affinity human antibodies to human angiopoietin-2
granted -
US 10875913
Methods of treatment using activatable anti-EGFR antibodies
granted -
US 10875920
Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
granted -
US 10876118
Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
granted -
US 10874676
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 10874687
Highly active compounds against COVID-19
granted -
US 10881708
Ang (1-7) derivative oligopeptides for the treatment of pain
granted -
US 10881684
Artificial invaplex formulated with deacylated lipopolysaccharide
granted -
US 10881646
Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers
granted -
US 10881644
Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
granted -
US 10881086
Genetically modified mouse whose genome comprises a humanized CD274 gene
granted -
US 10881104
Arthropod control composition, formulation, and method
granted -
US 10881630
Creatine oral supplementation using creatine hydrochloride salt
granted -
US 10881658
Methods for treating Huntington's disease
granted -
US 10881653
Tricyclic compounds and their use in the treatment of cancer
granted -
US 10881660
Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
granted -
US 10881666
Combination pharmaceutical agents as RSV inhibitors
granted -
US 10881669
Inhibitors of the plasmodial surface anion channel as antimalarials
granted -
US 10881691
Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo
granted -
US 10882895
Nucleic acid encoding angiopoietin-2 specific Tie2 receptor
granted -
US 10881738
Oligomer-beta blocker conjugates
granted -
US 10881722
Epizootic hemorrhagic disease vaccine
granted -
US 10881696
Network-based microbial compositions and methods
granted -
US 10881689
Materials and methods for engineering cells and uses thereof in immuno-oncology
granted -
US 10881698
Diagnosis and treatment for respiratory tract diseases
granted -
US 10881714
Methods and compositions for oral administration of proteins
granted -
US 10883980
Methods and compositions for inhibiting hepatitis E virus
granted -
US 10883994
Identification of cancer stem cells markers and use of same for diagnosis and treatment
granted -
US 10883107
Polynucleotide agents targeting factor XII (hageman factor) (F12) and methods of use thereof
granted -
US 10883104
Compositions and methods for modulating apolipoprotein (a) expression
granted -
US 10883119
Methods and compositions for delivery of biologics
granted -
US 10881720
Nanoparticles for immune stimulation
granted -
US 10883094
Transposase polypeptides and uses thereof
granted -
US 10882903
Methods and compositions for treating an alphavirus infection
granted -
US 10881748
Nitroxide containing amyloid binding agents for imaging and therapeutic uses
granted -
US 10881742
Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
granted -
US 10881735
Phase change nanodroplet conjugates for targeted delivery
granted -
US 10883117
Adeno-associated virus variants and methods of use thereof
granted -
US 10882886
Adeno-associated virus polynucleotides, polypeptides and virions
granted
Frequently asked questions
How many pharma patents expire in 2040?
1,866 published patents in our USPTO index have expiration dates falling in calendar year 2040.